Noble Capital Markets Served As Sole Placement Agent To Ocugen (OCGN) In $20mm Direct Offering

Noble Capital Markets is pleased to announce its role as Sole Placement Agent in the completion of Ocugen’s recent direct offering of $20,000,000 of its common stock at a price of $1.00 per share. The transaction priced on August 8, 2025.

Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

This transaction highlights Noble’s ongoing commitment to providing strategic capital markets and advisory services to middle-market companies across a wide range of sectors. With deep sector knowledge and a client-first approach, Noble supports companies throughout their lifecycle — from capital formation to M&A execution. 

For more information on Noble’s investment banking services, click here

For more information on this transaction, contact Nathan Cali @ ncali@noblecapitalmarkets.com